RGNX · REGENXBIO Inc. · Investor Relations
$7.47
+0.32 (+4.48%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 14, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$471.99M
Shares
66.01M
Volume · Oct 20
867.03K
Avg daily vol (3M)
1.38M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2026-10-20 | SURA-VEC IN WET AMD: CLINICAL PROGRAM OVERVIEW AND EXPERT PERSPECTIVES | Webcast |
| 2026-09-16 | Morgan Stanley 24th Annual Global Healthcare Conference | Conference |
| 2026-09-15 | Baird 2026 Global Healthcare Conference | Conference |
| 2026-08-06 | Q2 FY2026 Earnings conference call (announced in 8-K) | Earnings call |
| 2026-05-26 | Stifel 2026 Virtual Ophthalmology Forum | Event |
| 2026-05-20 | 2026 RBC Capital Markets Global Healthcare Conference | Conference |
| 2026-05-14 | REGENXBIO: TOPLINE RESULTS FROM PIVOTAL TRIAL OF RGX-202 | Earnings call |
| 2026-03-05 | Q4 2025 REGENXBIO INC. EARNINGS CONFERENCE CALL | Earnings call |
| 2026-01-14 | THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE | Conference |
Source: https://ir.regenxbio.com/
Key facts
CIK
1590877
CUSIP
75901B107
13F (30d)
15 filings
15 filers
Visit website
Investor relations